Proteasome inhibitors in cancer therapy
EE Manasanch, RZ Orlowski - Nature reviews Clinical oncology, 2017 - nature.com
The ubiquitin proteasome pathway was discovered in the 1980s to be a central component
of the cellular protein-degradation machinery with essential functions in homeostasis, which …
of the cellular protein-degradation machinery with essential functions in homeostasis, which …
The proteasome and proteasome inhibitors in multiple myeloma
S Gandolfi, JP Laubach, T Hideshima… - Cancer and Metastasis …, 2017 - Springer
Proteasome inhibitors are one of the most important classes of agents to have emerged for
the treatment of multiple myeloma in the past two decades, and now form one of the …
the treatment of multiple myeloma in the past two decades, and now form one of the …
Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma
Background Ixazomib is an oral proteasome inhibitor that is currently being studied for the
treatment of multiple myeloma. Methods In this double-blind, placebo-controlled, phase 3 …
treatment of multiple myeloma. Methods In this double-blind, placebo-controlled, phase 3 …
Smoldering multiple myeloma
Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cell disorder. SMM
is distinguished from monoclonal gammopathy of undetermined significance by a much …
is distinguished from monoclonal gammopathy of undetermined significance by a much …
Drug development targeting the ubiquitin–proteasome system (UPS) for the treatment of human cancers
X Zhang, S Linder, M Bazzaro - Cancers, 2020 - mdpi.com
Cancer cells are characterized by a higher rate of protein turnover and greater demand for
protein homeostasis compared to normal cells. In this scenario, the ubiquitin–proteasome …
protein homeostasis compared to normal cells. In this scenario, the ubiquitin–proteasome …
Novel agents in the treatment of multiple myeloma: a review about the future
L Naymagon, M Abdul-Hay - Journal of hematology & oncology, 2016 - Springer
Multiple myeloma (MM) is a disease that affects plasma cells and can lead to devastating
clinical features such as anemia, lytic bone lesions, hypercalcemia, and renal disease. An …
clinical features such as anemia, lytic bone lesions, hypercalcemia, and renal disease. An …
Boron-Containing heterocycles as promising pharmacological agents
The incorporation of the “magic” boron atom has been established as an important new
strategy in the field of medicinal chemistry as boron compounds have been shown to form …
strategy in the field of medicinal chemistry as boron compounds have been shown to form …
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials
Background Daratumumab showed encouraging efficacy as monotherapy in patients with
heavily pretreated multiple myeloma in the GEN501 and SIRIUS studies. Here we report a …
heavily pretreated multiple myeloma in the GEN501 and SIRIUS studies. Here we report a …
[HTML][HTML] Proteasome inhibitors
BA Teicher, JE Tomaszewski - Biochemical pharmacology, 2015 - Elsevier
Proteasome inhibitors have a 20 year history in cancer therapy. The first proteasome
inhibitor, bortezomib (Velcade, PS-341), a break-through multiple myeloma treatment …
inhibitor, bortezomib (Velcade, PS-341), a break-through multiple myeloma treatment …
Targeting the ubiquitin-proteasome system for cancer therapeutics by small-molecule inhibitors
G LaPlante, W Zhang - Cancers, 2021 - mdpi.com
Simple Summary The ubiquitin-proteasome system regulates multiple facets of protein
homeostasis to modulate signal transduction in numerous biological processes. Not …
homeostasis to modulate signal transduction in numerous biological processes. Not …